We are live on ! Find out more
CYCN icon

Cyclerion Therapeutics
CYCN

56 hedge funds and large institutions have $40.7M invested in Cyclerion Therapeutics in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

553% more call options, than puts

Call options by funds: $705K | Put options by funds: $108K

0.12% less ownership

Funds ownership: 2.85% → 2.73% (-0.12%)

8% less funds holding

Funds holding: 61 → 56 (-5)

23% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 13

24% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 17

46% less capital invested

Capital invested by funds: $75.8M → $40.7M (-$35.1M)

Holders
56
Holders Change
-5
Holders Change %
-8.2%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
10
Reduced
13
Closed
17
Calls
$705K
Puts
$108K
Net Calls
+$597K
Net Calls Change
-$537K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.04M
2
PVI
Pura Vida Investments
New York
+$825K
3
Renaissance Technologies
Renaissance Technologies
New York
+$646K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$590K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$178K

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$4.93M
2
Two Sigma Investments
Two Sigma Investments
New York
-$598K
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$321K
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$298K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$280K
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
26
Prelude Capital Management
New York
$133K +$82.8K +1,752 +82%
Morgan Stanley
27
Morgan Stanley
New York
$125K -$3.87K -82 -2%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$114K – – –
BFM
29
Boothbay Fund Management
New York
$87K – – –
IVP
30
Intrinsic Value Partners
Arizona
$87K +$120K +2,533 New
Susquehanna International Group
31
Susquehanna International Group
Pennsylvania
$48K -$64.7K -1,370 -50%
Group One Trading
32
Group One Trading
Illinois
$44K -$19.8K -420 -25%
Walleye Capital
33
Walleye Capital
New York
$44K +$59.9K +1,267 New
TRCT
34
Tower Research Capital (TRC)
New York
$39K -$14.2K -300 -21%
Verition Fund Management
35
Verition Fund Management
Connecticut
$34K – – –
Wolverine Trading
36
Wolverine Trading
Illinois
$29K +$42.4K +898 New
Charles Schwab
37
Charles Schwab
California
$27K – – –
CSS
38
Cubist Systematic Strategies
Connecticut
$24K +$32.9K +696 New
DC
39
Davenport & Co
Virginia
$22K +$30.2K +640 New
Marshall Wace
40
Marshall Wace
United Kingdom
$18K +$24.7K +522 New
UBS AM
41
UBS AM
Illinois
$17.5K – – –
Simplex Trading
42
Simplex Trading
Illinois
$11K +$15.4K +327 New
SC
43
Sawyer & Company
Massachusetts
$7K – – –
SWM
44
Spire Wealth Management
Virginia
$2K +$2.55K +54 New
Bank of America
45
Bank of America
North Carolina
$1K -$142 -3 -12%
Carson Wealth (CWM LLC)
46
Carson Wealth (CWM LLC)
Nebraska
$1K +$709 +15 New
HNWAG
47
High Net Worth Advisory Group
Florida
$1K +$1.18K +25 New
BNP Paribas Financial Markets
48
BNP Paribas Financial Markets
France
$494 – – –
EC
49
EcoR1 Capital
California
– -$4.93M -80,314 Closed
Jacobs Levy Equity Management
50
Jacobs Levy Equity Management
New Jersey
– -$280K -4,564 Closed
1
2
3

CYCN Hedge Fund Activity: Q4 2021 in Review

56 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q4 2021, worth a combined $40.7M — down 46% from $75.8M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of CYCN and 13 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 10 added.

The largest buyer was Vanguard Group, adding an estimated $1.04M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $4.93M sold.

  • 56 institutional investors held Cyclerion Therapeutics (CYCN) as of Q4 2021, down from 61 in Q3 2021.
  • Funds reported $40.7M of Cyclerion Therapeutics stock for Q4 2021, down 46% quarter-over-quarter.
  • 13 funds opened new Cyclerion Therapeutics positions in Q4 2021 and 17 closed out, a net change of -4 holders.
  • The largest Cyclerion Therapeutics buyer in Q4 2021 was Vanguard Group, an estimated $1.04M added.
  • The largest Cyclerion Therapeutics seller in Q4 2021 was EcoR1 Capital, an estimated $4.93M sold.

Based on aggregated 13F filings for Q4 2021.